Molecular and Cellular Biology, April 2001, p. 2608-2616, Vol. 21, No. 7
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.7.2608-2616.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Institute for Neurodegenerative Diseases1 and Departments of Neurology,2 Pathology,3 Cellular and Molecular Pharmacology,4 Medicine,5 and Biochemistry and Biophysics,6 University of California at San Francisco, San Francisco, California 94143
Received 29 September 2000/Returned for modification 1 December 2000/Accepted 18 December 2000
An abridged prion protein (PrP) molecule of 106 amino acids,
designated PrP106, is capable of forming infectious miniprions in
transgenic mice (S. Supattapone, P. Bosque, T. Muramoto, H. Wille, C. Aagaard, D. Peretz, H.-O. B. Nguyen, C. Heinrich, M. Torchia, J. Safar, F. E. Cohen, S. J. DeArmond, S. B. Prusiner, and
M. Scott, Cell 96:869-878, 1999). We removed additional sequences from
PrP106 and identified a 61-residue peptide, designated PrP61, that
spontaneously adopted a protease-resistant conformation in neuroblastoma cells. Synthetic PrP61 bearing a carboxy-terminal lipid
moiety polymerized into protease-resistant,
-sheet-enriched amyloid
fibrils at a physiological salt concentration. Transgenic mice
expressing low levels of PrP61 died spontaneously with ataxia. Neuropathological examination revealed accumulation of
protease-resistant PrP61 within neuronal dendrites and cell bodies,
apparently causing apoptosis. PrP61 may be a useful model for
deciphering the mechanism by which PrP molecules acquire protease
resistance and become neurotoxic.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|